CTE and Addiction: The Brain Injury Connection Athletes Face

What Is CTE and How Does It Develop in Athletes?

Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disease caused by repeated traumatic brain injuries, including both diagnosed concussions and the thousands of subconcussive impacts that accumulate over years of participation in contact sports. First identified in boxers in the 1920s under the term "dementia pugilistica," CTE gained widespread public attention following the pioneering work of Dr. Bennet Omalu, who in 2005 published the first case study of CTE in an NFL player, Pittsburgh Steelers center Mike Webster. Since then, Boston University's CTE Center has identified the disease in the brains of hundreds of former athletes across football, hockey, soccer, rugby, and combat sports.

The pathological hallmark of CTE is the abnormal accumulation of hyperphosphorylated tau protein in neurons and astrocytes, forming neurofibrillary tangles that progressively spread throughout the brain. Unlike the beta-amyloid plaques characteristic of Alzheimer's disease, CTE tau pathology typically begins in the depths of cortical sulci near small blood vessels and spreads outward in a distinctive pattern. This tau accumulation triggers a cascade of neuroinflammation, neuronal death, and white matter degeneration that manifests clinically as cognitive decline, emotional instability, impulsive behavior, depression, and in advanced stages, progressive dementia.

The relationship between CTE and substance use disorders is rooted in the specific brain regions most vulnerable to tau pathology. The prefrontal cortex, which governs executive functions such as impulse control, planning, risk assessment, and behavioral inhibition, is among the earliest and most severely affected regions. The amygdala, hippocampus, and deep brain structures involved in reward processing and emotional regulation are also frequently compromised. This pattern of neurodegeneration creates a neurological substrate that is uniquely vulnerable to the development and progression of addictive behaviors.

The Neuroscience Linking CTE to Addiction Vulnerability

The connection between CTE and addiction is not merely correlational; it is mechanistic and neurobiological. CTE-related tau pathology damages the brain's executive control network, centered in the prefrontal cortex, which serves as the brain's braking system for impulsive behavior. When this network is compromised, an individual's ability to resist cravings, evaluate long-term consequences, and regulate emotional responses to stress is significantly diminished. Neuroimaging studies of individuals with traumatic brain injuries show reduced prefrontal activation during decision-making tasks, a pattern that closely mirrors the neural signatures observed in individuals with established substance use disorders.

Beyond impulse control deficits, CTE affects the mesolimbic dopamine pathway, the brain's primary reward circuit connecting the ventral tegmental area (VTA) to the nucleus accumbens. Repeated head trauma triggers neuroinflammation that disrupts dopamine receptor density and signaling efficiency in these structures, creating a state of reward deficiency in which normal pleasurable activities no longer produce adequate dopamine responses. This neurological state drives affected individuals toward substances and behaviors that artificially elevate dopamine levels, creating a biological push toward addiction that operates independently of psychological or social risk factors.

Research published in the journal Neurology in 2019 found that former contact sport athletes with a history of repetitive head impacts were significantly more likely to report substance abuse problems than athletes in non-contact sports, even after controlling for factors such as chronic pain, depression, and socioeconomic status. This finding suggests that the neurodegenerative changes associated with repetitive head trauma create an independent risk pathway to addiction, distinct from the psychosocial factors that also elevate substance use risk in athlete populations.

Recognizing CTE-Related Behavioral Changes and Substance Use

CTE presents along a clinical spectrum that researchers have divided into behavioral/mood and cognitive subtypes, with many individuals exhibiting features of both. The behavioral/mood subtype, which typically emerges in individuals in their late twenties to early forties, is characterized by impulsivity, explosiveness, emotional volatility, depression, and paranoia. These symptoms are frequently the earliest manifestations of CTE and are commonly misdiagnosed as primary psychiatric conditions, personality disorders, or simple consequences of the difficult transition from professional sports to civilian life.

Substance use often escalates during this behavioral/mood phase of CTE, as affected individuals attempt to manage increasingly uncontrollable emotions, sleep disturbances, and chronic headaches through self-medication. Alcohol is the most commonly misused substance among individuals with suspected CTE, followed by prescription opioids, benzodiazepines, and cannabis. The self-medication pattern creates a vicious cycle in which substance use accelerates neurodegeneration while the progressing brain disease intensifies the psychological distress that drives continued substance use.

Family members and loved ones of former athletes may notice a constellation of warning signs that suggest the intersection of CTE-related brain changes and developing substance use disorder. These include dramatic personality changes that seem disproportionate to life circumstances, increasingly impulsive or reckless behavior, memory problems that exceed normal age-related forgetfulness, withdrawal from previously enjoyed activities and relationships, escalating use of alcohol or other substances, and episodes of explosive anger that are uncharacteristic of the individual's pre-injury personality. Recognizing these patterns early creates opportunities for intervention that can significantly slow functional decline and prevent the catastrophic consequences of untreated addiction.

• Dramatic personality changes disproportionate to circumstances
• Escalating impulsivity and risk-taking behavior
• Increasing use of alcohol or drugs to manage mood
• Memory lapses and difficulty with planning or organization
• Episodes of explosive, uncharacteristic anger
• Withdrawal from relationships and previously enjoyed activities
• Chronic headaches, sleep disturbances, and emotional volatility

Treatment Approaches for Co-Occurring CTE and Addiction

Treating substance use disorders in individuals with known or suspected CTE requires a neurologically informed approach that accounts for the cognitive impairments and emotional dysregulation inherent to the disease. Standard addiction treatment protocols often rely heavily on verbal processing, abstract reasoning, and the ability to maintain focus during lengthy individual and group therapy sessions. For individuals with CTE-related cognitive deficits, these modalities may need to be adapted through shorter session durations, greater use of visual aids and written materials, repetition of key concepts across multiple sessions, and incorporation of experiential and somatic therapies that do not depend primarily on verbal processing.

Medication-assisted treatment can be particularly beneficial for individuals with CTE and co-occurring substance use disorders, as pharmacological interventions address the neurobiological disruptions driving addiction at the neurochemical level. For alcohol use disorder, naltrexone can help compensate for the reward system dysregulation caused by CTE-related neurodegeneration. For opioid use disorder, buprenorphine or extended-release naltrexone provide neurological stabilization while reducing the decision-making burden on a compromised prefrontal cortex. Psychiatric medications targeting the depression, anxiety, and emotional volatility associated with CTE may also reduce the psychological drivers of self-medication.

At Trust SoCal, our treatment team conducts thorough neuropsychological assessments to identify cognitive strengths and deficits that inform individualized treatment planning. Located in Fountain Valley, Orange County, we understand that effective addiction treatment must meet each individual where they are neurologically, not just psychologically. Our programs integrate cognitive rehabilitation strategies, adapted therapeutic modalities, medication management, and family education to provide comprehensive care for the complex needs of individuals living with brain injury-related substance use disorders. Call (949) 280-8360 to discuss how our programs can be tailored to address the unique challenges of CTE-related addiction.